March 2011. Volume 7. Number 1

The 10 and 13 valent pneumococcal conjugated vaccines could prevent most of the cases of invasive pneumococcal disease worldwide

 
 
 
 
 
 
 
 
 
 
Rating: 4.75 (2 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L. (2010) Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project. PLoS Med. 2010;7(10):e1000348.
Reviewers: Gimeno Díaz de Atauri Á1, Rivas Juesas C2.
1Servicio de Pediatría. Hospital Puerta de Hierro. Madrid. España.
2Servicio de Pediatría. Hospital de Sagunto. Valencia. España.
Correspondence: Álvaro Gimeno Díaz de Atauri. Email: agdrizos@hotmail.com
Reception date: 20/01/2011
Acceptance date: 31/01/2011
Publication date: 03/02/2011

Abstract

Author´s conclusion: a limited number of serotypes cause most of invasive pneumococcal disease (IPD) worldwide. The serotypes included in existing PCV formulations account for 49%-88% of deaths in Africa and Asia, where the morbimortality is the highest, but few children have access to these vaccines.

Reviewer´s commentary: although the study has some limitations, it looks like there is not great variability worldwide between serotypes causing IPD mortality and most of them are included in the coverage of the new 10- and 13-valent vaccines. More analysis are needed on the potential benefit of implementing universal vaccination in the most affected countries by this disease.

How to cite this article

Gimeno Díaz de Atauri Á, Rivas Juesas C. Las vacunas antineumocócicas disponibles podrían aportar cobertura para la mayor parte de los casos de enfermedad neumocócica invasiva en todos los continentes. Evid Pediatr. 2011;7:14.

AVC | Critically appraised articles

Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L. (2010) Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project. PLoS Med. 2010;7(10):e1000348.
Reviewers: Gimeno Díaz de Atauri Á1, Rivas Juesas C2.
1Servicio de Pediatría. Hospital Puerta de Hierro. Madrid. España.
2Servicio de Pediatría. Hospital de Sagunto. Valencia. España.
Correspondence: Álvaro Gimeno Díaz de Atauri. Email: agdrizos@hotmail.com
Reception date: 20/01/2011
Acceptance date: 31/01/2011
Publication date: 03/02/2011

How to cite this article

Gimeno Díaz de Atauri Á, Rivas Juesas C. Las vacunas antineumocócicas disponibles podrían aportar cobertura para la mayor parte de los casos de enfermedad neumocócica invasiva en todos los continentes. Evid Pediatr. 2011;7:14.

References

  1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N et al; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
  2. Rivas Juesas C, González de Dios J. Prevalencia y mortalidad de los serotipos de neumococo: elemento clave para el desarrollo de nuevas vacunas. Evid Pediatr. 2009;5:61.
  3. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Wich pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30:100-21.
  4. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30:122-40.
03/02/2011

Linked Comment